Biocryst
Navenibart
STAR-0215 / Hereditary angioedema / Phase 3 / Hereditary angioedema prophylaxis
Pipeline Watchlist
Company Pipelines
Recent additions
14 daysbiocryst.com
Bioatla
BA3362
Oncology
Bioatla
BA3241
Oncology / Preclinical / Solid tumors
Bioatla
BA3311
Oncology / Preclinical / Solid tumors
Bioatla
BA3142
Oncology / Preclinical / Solid tumors
Bioatla
BA3151
Oncology / Preclinical / Breast cancer
Axsome
AXS-20
CNS / Phase 3-enabling / Schizophrenia
Autolus
AUTO4
Oncology / Phase 1 / PTCL
Autolus
obe-cel
obecabtagene autoleucel / Oncology; Autoimmune disease / Phase 1 / B-NHL
Aura Biosciences
belzupacap sarotalocan
AU-011 / oncology / Phase 3 / early choroidal melanoma (small choroidal melanoma and/or indeterminate lesions)
Ataibeckley
Novel 5-HT2A Receptor Agonists
Mental health / In development / Opioid Use Disorder
Ascendis Pharma
TransCon CNP + TransCon hGH
navapegritide + lonapegsomatropin / Endocrinology rare diseases / Phase 2 / Achondroplasia (children aged 2-11)
Companies
ASNDAscendis Pharma
5assets
Ascendis Pharma
- TransCon hGHlonapegsomatropin / SKYTROFA / growth hormone receptor / long-acting TransCon prodrug of somatropin / Endocrinology rare diseasesTurner syndrome (children aged 1-10)Phase 2New InsiGHTS TrialUnited StatesTurner syndrome, ISS, SHOX deficiency, SGA (children aged 2-17)Phase 3HighLiGHts TrialMultinationalPediatric GHDPhase 3Partner programChinaJapan
- TransCon CNPnavapegritide / YUVIWEL / C-type natriuretic peptide pathway / long-acting TransCon prodrug of CNP / Endocrinology rare diseasesAchondroplasia (infants aged 0-<2)Pivotal Phase 2reACHin TrialMultinationalAchondroplasia (children aged 2-11)Pivotal Phase 2ApproaCH TrialMultinationalAchondroplasia (adolescents aged 12-18)Pivotal Phase 2bteACH TrialMultinational
- TransCon CNP + TransCon hGHnavapegritide + lonapegsomatropin / CNP pathway + growth hormone receptor / combination of long-acting TransCon prodrugs / Endocrinology rare diseasesAchondroplasia (children aged 2-11)Phase 2COACH TrialMultinational
- TransCon PTHpalopegteriparatide / YORVIPATH / parathyroid hormone receptor / long-acting TransCon prodrug of PTH / Endocrinology rare diseasesAdult hypoparathyroidism (dosing expansion)Phase 3PaTHway60 TrialUnited StatesAdult hypoparathyroidismPhase 3Partner programChina
- TransCon IL-2 β/γ (Systemic)IL-2 beta/gamma receptor / TransCon prodrug cytokine / OncologyVarious tumor typesPhase 2IL-Believe TrialMultinational